Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roivant/Roche: Did Pfizer Miss Out?

Merck/Prometheus Deal Changed TL1A Market Dynamics

Oct 23 2023

• By Jessica Merrill

question mark — Pfizer's deal with Roivant raises questions • Source: Shutterstock

Related Content

Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

May 24 2022

Pfizer Gets First Approval Of Arena’s Etrasimod, In Ulcerative Colitis

Oct 13 2023

‘It’s A Very Different Story,’ Pfizer CEO Bourla Says Of Cuts To Match COVID Revenue

Oct 16 2023

Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy

Apr 17 2023

Pfizer Returns To Roivant As Development Partner For A Second Time

Dec 01 2022

Related Companies

Pfizer Inc.

Roche Holding AG

Merck & Co., Inc.

Sanofi

Prometheus Biosciences Inc.

Teva Pharmaceutical Industries Ltd.

Arena Pharmaceuticals, Inc.

Seagen Inc.

Priovant Therapeutics, Inc.

Dermavant Sciences Inc.

Additional Topics

Deals M & A Business Strategies Commercial Immune Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.